查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529610

口腔內給藥系統市場規模、佔有率和趨勢分析報告：2024-2030 年按類型、應用、最終用途、地區和細分市場進行的預測

Buccal Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Buccal Tablets & Lozenges), By Application (Pain Management, Smoking Cessation, Angina Pectoris), By End-use, By Region, And Segment Forecast, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

口內給藥系統市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球口腔給藥系統市場規模預計將達到65.6億美元。

預計2024年至2030年該市場將以6.2%的複合年成長率成長。口腔給藥系統在過去十年中取得了巨大的發展動能。消除首過代謝、pH敏感藥物的快速吸收、不與胃酸相互作用、比口服給藥更快起效、最小的副作用以及減少的藥物分解是推動市場成長的一些因素。口腔內給藥被老年患者和吞嚥困難患者廣泛接受。

Generex、NovaDel、Biodiversity Sciences International 和 Transcept Pharmaceuticals 等領先公司正在持續開發快速霧劑、貼片和含片等重要藥物，如胰島素、肝素、氫可酮、長效止痛藥和一些抗心臟藥物。如果這項研究商業化，藥效起效會更快，而且不會出現藥物劣化的情況，因此最終將成為一大救星。儘管市場相關人員的研發活動活性化，但由於 COVID-19 大流行的爆發，銷售額和收益卻急劇下降。非新冠疫情藥品市場也受到重創，導致口服給藥市場下滑。不過，預計到 2022 年將恢復。

口腔給藥系統市場報告重點：

  • 由於患者廣泛接受，口錠劑和含片類型將在 2023 年佔據最大的銷售佔有率。
  • 2023 年，無菸應用領域佔最大佔有率。口服藥物遞送通常是治療吸菸或尼古丁成癮患者的最優選和最有效的製劑。
  • 由於老年患者入院人數較多和藥品供應充足，醫院最終用戶細分市場在 2023 年獲得了最大的收益佔有率。
  • 由於該地區擁有大量主要製造商以及不斷擴大的研究，北美在 2023 年佔據了最大的銷售佔有率。

目錄

第1章調查方法和範圍

第2章執行概述

第3章口腔內給藥系統市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 口腔內給藥系統市場分析工具
    • 波特的分析
    • PESTEL分析

第4章口腔內給藥系統市場：類型估計和趨勢分析

  • 細分儀表板
  • 口內給藥系統市場：類型變異分析，2023 年及 2030 年
  • 舌下膜
  • 口服錠劑/含片
  • 口腔內噴霧

第5章口腔內給藥系統市場：按應用、估計和趨勢分析

  • 細分儀表板
  • 口內給藥系統市場：2023 年和 2030 年應用變化分析
  • 疼痛管理
  • 禁止抽煙
  • 心絞痛
  • 其他

第6章口腔內給藥系統市場：最終用途、估計與趨勢分析

  • 細分儀表板
  • 口內給藥系統市場：最終用途變化分析，2023 年和 2030 年
  • 醫院
  • 門診中心
  • 其他（診所、居家醫療/OTC）

第7章口腔內給藥系統市場：區域估計與趨勢分析

  • 2023 年和 2030 年，按地區分類的口內給藥系統市場佔有率，百萬美元
  • 北美洲
    • 2018-2030年北美口腔內給藥系統市場預測及預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年歐洲口腔內給藥系統市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018-2030年亞太地區口腔內給藥系統市場估計與預測
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2018-2030年拉丁美洲口腔內給藥系統市場估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018-2030年中東和非洲口腔內給藥系統市場估計與預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Pfizer Inc.
    • Generex Biotechnology Corporation（LUMITOS AG）
    • ARx, LLC.
    • Catalent, Inc
    • Collegium Pharmaceutical
    • Cynapsus Therapeutics Inc.
    • Endo, Inc.
    • Indivior PLC
簡介目錄
Product Code: GVR-4-68038-397-3

Buccal Drug Delivery Systems Market Growth & Trends:

The global buccal drug delivery systems market size is expected to reach USD 6.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 6.2% from 2024 to 2030. Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.

Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges. Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, asteep decline was observed in the sales and revenue gainsdue to the outbreak of the Covid-19 pandemic. Except for covid medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.

Buccal Drug Delivery Systems Market Report Highlights:

  • The buccal tablets and lozenges type segment accounted for the largest revenue share in 2023 due to its wider acceptance among patients
  • The smoking cessation application segment held the largest share in 2023. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
  • The hospital end-user segment captured the largest revenue share in 2023 owing to a large number of admissions of geriatric patients and abundant medication supplies
  • North America held the largest revenue share in 2023 due to a large number of leading manufacturers and growing research in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Buccal Drug Delivery Systems Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Buccal Drug Delivery Systems Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Buccal Drug Delivery Systems Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Buccal Drug Delivery Systems Market: Solution Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Sublingual Films
    • 4.3.1. Sublingual Films And Wafers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Buccal Tablets/Lozenges
    • 4.4.1. Buccal Tablets/Lozenges Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Oral Sprays
    • 4.5.1. Oral Sprays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Buccal Drug Delivery Systems Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Buccal Drug Delivery Systems Market: Technology Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Pain Management
    • 5.3.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Smoking Cessation
    • 5.4.1. Smoking Cessation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Angina Pectoris
    • 5.5.1. Angina Pectoris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Buccal Drug Delivery Systems Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Buccal Drug Delivery Systems Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Ambulatory Centers
    • 6.4.1. Ambulatory Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others (Clinics, Home Health/OTC)
    • 6.5.1. Others (Clinics, Home Health/OTC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Buccal Drug Delivery Systems Market: Regional Estimates & Trend Analysis

  • 7.1. Buccal Drug Delivery Systems Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Buccal Drug Delivery Systems Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Teva Pharmaceutical Industries Ltd.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/Strategic Initiatives
    • 8.4.2. GSK plc
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/Strategic Initiatives
    • 8.4.3. Pfizer Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/Strategic Initiatives
    • 8.4.4. Generex Biotechnology Corporation (LUMITOS AG)
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/Strategic Initiatives
    • 8.4.5. ARx, LLC.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/Strategic Initiatives
    • 8.4.6. Catalent, Inc
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/Strategic Initiatives
    • 8.4.7. Collegium Pharmaceutical
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/Strategic Initiatives
    • 8.4.8. Cynapsus Therapeutics Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/Strategic Initiatives
    • 8.4.9. Endo, Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/Strategic Initiatives
    • 8.4.10. Indivior PLC
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/Strategic Initiatives